These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 31810908)

  • 21. Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of Clusterin/Apolipoprotein J.
    Lourda M; Trougakos IP; Gonos ES
    Int J Cancer; 2007 Feb; 120(3):611-22. PubMed ID: 17096323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of cisplatin resistance and targeting of cancer stem cells: Adding glycosylation to the equation.
    Ferreira JA; Peixoto A; Neves M; Gaiteiro C; Reis CA; Assaraf YG; Santos LL
    Drug Resist Updat; 2016 Jan; 24():34-54. PubMed ID: 26830314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of tumour resistance against chemotherapeutic agents in veterinary oncology.
    Klopfleisch R; Kohn B; Gruber AD
    Vet J; 2016 Jan; 207():63-72. PubMed ID: 26526523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The anti-proliferative and apoptotic effects of crocin on chemosensitive and chemoresistant cervical cancer cells.
    Mollaei H; Safaralizadeh R; Babaei E; Abedini MR; Hoshyar R
    Biomed Pharmacother; 2017 Oct; 94():307-316. PubMed ID: 28763753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of mitochondrial respiration overcomes hepatocellular carcinoma chemoresistance.
    Sun Y; Xu H; Chen X; Li X; Luo B
    Biochem Biophys Res Commun; 2019 Jan; 508(2):626-632. PubMed ID: 30522865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What does not kill a tumour may make it stronger: In silico insights into chemotherapeutic drug resistance.
    Hamis S; Nithiarasu P; Powathil GG
    J Theor Biol; 2018 Oct; 454():253-267. PubMed ID: 29909142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
    Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
    Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acid ceramidase as a chemotherapeutic target to overcome resistance to the antitumoral effect of choline kinase α inhibition.
    Ramírez de Molina A; de la Cueva A; Machado-Pinilla R; Rodriguez-Fanjul V; Gomez del Pulgar T; Cebrian A; Perona R; Lacal JC
    Curr Cancer Drug Targets; 2012 Jul; 12(6):617-24. PubMed ID: 22515519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishment of in-vitro models of chemotherapy resistance.
    Watson MB; Lind MJ; Cawkwell L
    Anticancer Drugs; 2007 Aug; 18(7):749-54. PubMed ID: 17581296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical antitumor activity of the oral platinum analog satraplatin.
    Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro antiproliferation in prostate cancer cell lines with cytostatics and combinations with resistance modifiers.
    Pintér O; Mucsi I; Molnár J
    In Vivo; 2005; 19(1):253-9. PubMed ID: 15796183
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
    Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
    Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acquisition of anticancer drug resistance is partially associated with cancer stemness in human colon cancer cells.
    El Khoury F; Corcos L; Durand S; Simon B; Le Jossic-Corcos C
    Int J Oncol; 2016 Dec; 49(6):2558-2568. PubMed ID: 27748801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PGE
    Lin MC; Chen SY; He PL; Herschman H; Li HJ
    Int J Cancer; 2018 Sep; 143(6):1440-1455. PubMed ID: 29658109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of carfilzomib-resistant non-small cell lung cancer cell lines.
    Hanke NT; Imler E; Marron MT; Seligmann BE; Garland LL; Baker AF
    J Cancer Res Clin Oncol; 2018 Jul; 144(7):1317-1327. PubMed ID: 29766327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Addressing Drug Resistance in Cancer with Macromolecular Chemotherapeutic Agents.
    Park NH; Cheng W; Lai F; Yang C; Florez de Sessions P; Periaswamy B; Wenhan Chu C; Bianco S; Liu S; Venkataraman S; Chen Q; Yang YY; Hedrick JL
    J Am Chem Soc; 2018 Mar; 140(12):4244-4252. PubMed ID: 29504396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
    David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
    Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance.
    Ng CP; Bonavida B
    Adv Cancer Res; 2002; 85():145-74. PubMed ID: 12374285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines.
    Januchowski R; Sterzyńska K; Zaorska K; Sosińska P; Klejewski A; Brązert M; Nowicki M; Zabel M
    J Ovarian Res; 2016 Oct; 9(1):65. PubMed ID: 27756418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current status of methods to assess cancer drug resistance.
    Lippert TH; Ruoff HJ; Volm M
    Int J Med Sci; 2011 Mar; 8(3):245-53. PubMed ID: 21487568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.